Program
Levetiracetam
Also written as “Levetiracetam (Keppra)”, “levetiracetam” and “Levetiracetam 250 mg”.
Its studies are mostly in Epilepsy · Epilepsies, Partial · Seizures · Cognitive Dysfunction · Epilepsy, Generalized, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCB | 570 open or running | phase 4since Sep 8, 2005 | Mar 3, 2005 | none ahead |
| Hikma Pharmaceuticals | 40 open or running | no phasesince Jan 15, 2009 | Jan 15, 2009 | none ahead |
| Teva Pharmaceutical Industries | 40 open or running | phase 1since Feb 20, 2009 | Feb 20, 2009 | none ahead |
| AgeneBio | 20 open or running | phase 3since Mar 28, 2018 | Mar 28, 2018 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since May 26, 2010 | May 26, 2010 | none ahead |
| Ache Laboratorios Farmaceuticos | 10 open or running | phase 3since Jul 6, 2011 | Jul 6, 2011 | none ahead |
| Desitin Arzneimittel | 10 open or running | phase 1since Dec 1, 2025 | Dec 1, 2025 | none ahead |
| Novartis | 10 open or running | phase 1since Jul 24, 2009 | Jul 24, 2009 | none ahead |
Also a collaborator on its studies: pra-health-sciences and parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Sep 8, 2005.
- Jul 6, 2011Ache Laboratorios Farmaceuticos's first study: phase 3 study in EpilepsyNew to Ache Laboratorios FarmaceuticosAche Laboratorios Farmaceuticos · NCT01392768 · 126 enrolled
- Jul 12, 2011Phase 1 study in Healthy VolunteersUCB · NCT01394224 · 25 enrolled · United Kingdom
- Jul 13, 2011Phase 3 study in EpilepsyUCB · NCT01398956 · 44 enrolled · Japan
- Jul 29, 2011Phase 2 study in EpilepsyUCB · NCT01407523 · 16 enrolled · Japan
- Dec 9, 20112 phase 4 studiesUCB · NCT01491113, NCT01498822
- Jan 5, 2012Phase 3 study in EpilepsyUCB · NCT01506882 · 71 enrolled · Japan
- Jun 11, 20122 phase 1 studies in Human VolunteersUCB · NCT01618903, NCT01618877
- Nov 7, 2012Phase 1 study in Healthy VolunteersUCB · NCT01725009 · 32 enrolled · Japan
- Sep 26, 2013Phase 3 study in EpilepsyUCB · NCT01954121 · 436 enrolled · China
- Nov 6, 2015Phase 1 study in Healthy VolunteersUCB · NCT02602860 · 13 enrolled · United States
- Nov 8, 2017Phase 3 study in SeizuresUCB · NCT03340064 · 38 enrolled · Japan
- Mar 28, 2018AgeneBio's first study: phase 3 study in Cognitive DysfunctionNew to AgeneBioAgeneBio · NCT03486938 · 164 enrolled · United States, Canada
- Aug 3, 2023Phase 2 study in Cognitive DysfunctionAgeneBio · NCT05986721 · United States
- Dec 1, 2025Desitin Arzneimittel's first study: phase 1 study in Pharmacokinetic AnalysisNew to Desitin ArzneimittelDesitin Arzneimittel · NCT07393022 · 20 enrolled · Canada
TargetBeta
“Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker”ChEMBL 37, by rule
Studies
The newest 60 of 72 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07393022Pharmacokinetic Analysis · Canada | 1 | Completed | Desitin Arzneimittel | Jan 5, 2026 | 20 |
| NCT05986721Cognitive Dysfunction · United States | 2 | Withdrawn | AgeneBio | Jul 2028 | 0 |
| NCT03486938Cognitive Dysfunction · United States, Canada | 3 | Completed | AgeneBio | Nov 2, 2022 | 164 |
| NCT03340064Seizures · Japan | 3 | Completed | UCB | Jun 1, 2021 | 38 |
| NCT02602860Healthy Volunteers · United States | 1 | Completed | UCB | Sep 2017 | 13 |
| NCT01954121Epilepsy · China | 3 | Completed | UCB | Sep 2015 | 436 |
| NCT01725009Healthy Volunteers · Japan | 1 | Completed | UCB | Dec 2012 | 32 |
| NCT01618903Human Volunteers · China | 1 | Completed | UCB | Jul 2012 | 24 |
| NCT01618877Human Volunteers · China | 1 | Completed | UCB | Jul 2012 | 24 |
| NCT01506882Epilepsy · Japan | 3 | Completed | UCB | Oct 2013 | 71 |
| NCT01498822Epilepsy · Korea, Republic of | 4 | Completed | UCB | Jul 2014 | 353 |
| NCT01491113Healthy Subjects · Japan | 4 | Completed | UCB | Nov 2012 | 30 |
| NCT01407523Epilepsy · Japan | 2 | Completed | UCB | Feb 2012 | 16 |
| NCT01398956Epilepsy · Japan | 3 | Completed | UCB | Apr 2016 | 44 |
| NCT01394224Healthy Volunteers · United Kingdom | 1 | Completed | UCB | Sep 2011 | 25 |
| NCT01392768Epilepsy | 3 | Completed | Ache Laboratorios Farmaceuticos | Jul 2015 | 126 |
| NCT01375374Epilepsies, Partial · Austria, Germany, Spain | 3 | Terminated | UCB | Mar 2013 | 11 |
| NCT01292837Epilepsy · Japan | 3 | Completed | UCB | Jun 2013 | 13 |
| NCT01229735Epilepsy · Korea, Republic of | 4 | Completed | UCB | May 2015 | 343 |
| NCT01228747Epilepsy · China, Japan | 3 | Completed | UCB | Apr 2014 | 361 |
| NCT01132352Healthy · United States | 1 | Completed | Dr. Reddy's Laboratories | Oct 2003 | 24 |
| NCT01131897Healthy · United States | 1 | Completed | Dr. Reddy's Laboratories | Sep 2003 | 24 |
| NCT01063764Epilepsy · Japan | 3 | Completed | UCB | Apr 2011 | 73 |
| NCT00985348Healthy · United Kingdom | 1 | Completed | UCB | Oct 2009 | 26 |
| NCT00961441Epilepsy · United States | 2 | Completed | UCB | Mar 2010 | 25 |
| NCT00946751Seizures | 1 | Completed | Novartis | Mar 2004 | 20 |
| NCT00859521Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 2007 | 30 |
| NCT00859430Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 2007 | 22 |
| NCT00849862Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Nov 2005 | 22 |
| NCT00849485Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Nov 2005 | 22 |
| NCT00826787Seizures · United States | – | Completed | Hikma Pharmaceuticals | Aug 2005 | 29 |
| NCT00827320Seizures · United States | – | Completed | Hikma Pharmaceuticals | Jun 2007 | 26 |
| NCT00826865Seizures · United States | – | Completed | Hikma Pharmaceuticals | Aug 2005 | 27 |
| NCT00826722Seizures · United States | – | Completed | Hikma Pharmaceuticals | Jun 2007 | 30 |
| NCT00631150Epilepsy | 4 | Completed | UCB | Jul 2004 | 35 |
| NCT00630968Epilepsy | 4 | Completed | UCB | Feb 2004 | 1,541 |
| NCT00630630Epilepsy | 4 | Completed | UCB | Nov 2003 | 3 |
| NCT00630357Epilepsy | 4 | Completed | UCB | Jul 2004 | 14 |
| NCT00643500Epilepsies, Partial | 4 | Completed | UCB | May 2003 | 342 |
| NCT00615615Epilepsy | 3 | Completed | UCB | Mar 2003 | 216 |
| NCT00610454Epilepsy | 2 | Completed | UCB | Aug 2004 | 25 |
| NCT00612859Anxiety Disorders | 2 | Completed | UCB | Jun 2004 | 217 |
| NCT00600509Epilepsy | 2 | Completed | UCB | Jul 2003 | 216 |
| NCT00545012Seizures | 2 | Completed | UCB | May 2003 | 4 |
| NCT00544050Epilepsy | 2 | Completed | UCB | May 2003 | 13 |
| NCT00535392Epilepsy · United States, Belgium, France and more | 2 | Completed | UCB | Feb 2010 | 33 |
| NCT00505934Epilepsy · United States, Belgium, France and more | 2 | Completed | UCB | Mar 2010 | 19 |
| NCT00419393Epilepsy · United States, Mexico, Poland and more | 3 | Completed | UCB | Mar 2010 | 190 |
| NCT00419094Epilepsy · United States, Mexico, Poland and more | 3 | Completed | UCB | Sep 2009 | 228 |
| NCT00367432Epilepsy · Japan | 3 | Completed | UCB | Dec 2010 | 398 |
| NCT00368069Epilepsy · Brazil, Finland, India and more | 3 | Completed | UCB | May 2007 | 158 |
| NCT00291655Epilepsy · Belgium, Bulgaria, Finland and more | 3 | Completed | UCB | Apr 2008 | 130 |
| NCT00280696Epilepsies, Partial · Japan | 3 | Completed | UCB | Nov 2007 | 352 |
| NCT00245713Epilepsies, Partial | 4 | Completed | UCB | Nov 2004 | 40 |
| NCT00175955Dyskinesia, Drug-Induced · Belgium, Bulgaria | 2 | Completed | UCB | Dec 2005 | 70 |
| NCT00175903Epilepsy · Australia, Austria, Belgium and more | 3 | Completed | UCB | Oct 2007 | 1,701 |
| NCT00175890Epilepsies, Partial · United States, Argentina, Belgium and more | 3 | Completed | UCB | Jan 2007 | 116 |
| NCT00160654Epilepsies, Partial · Hong Kong, Malaysia, Philippines and more | 4 | Completed | UCB | Dec 12, 2006 | 251 |
| NCT00160628Epilepsies, Partial | 3 | Completed | UCB | Oct 2004 | 100 |
| NCT00160615Epilepsies, Partial | 3 | Completed | UCB | Jan 17, 2007 | 154 |
How it is read
Names in the registry
- “Levetiracetam”, 52 entries
- “Levetiracetam (Keppra)”, 4 entries
- “levetiracetam”, 3 entries
- “Levetiracetam 250 mg”, 3 entries
- “Levetiracetam 500 mg”, 3 entries
Conditions, from the studies’ own filings
- Epilepsy, 26 studies
- Epilepsies, Partial, 13 studies
- Seizures, 8 studies
- Cognitive Dysfunction, 2 studies
- Epilepsy, Generalized, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.